Trial intelligence / Profile preview

Sugammadex in subjects with normal or impaired renal function

2005-005050-47Phase 3Completed

Sponsor
Organon & Co.
Start
Dec 2005
Modality
Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Phase 3, randomised trial of Sugammadex (2 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of neuromuscular function. Started Dec 2005; status: completed.

02

Drugs

Sugammadex

Beyond the preview

Go deeper on 2005-005050-47.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005050-47.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call